Except for C-C chemokine receptor 7 expression,monocyte-derived dendritic cells from patients with multiple sclerosis are functionally comparable to those of healthy controls |
| |
| Affiliation: | 1. Laboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (Vaxinfectio), Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium;2. Department of Neurology, National Center for Multiple Sclerosis, Melsbroek, Belgium and Center for Neurosciences, Universitair Ziekenhuis Brussel en Vrije Universiteit Brussel, Belgium;3. Laboratory of Neurology, Born Bunge Institute, Translational Neurosciences, Faculty and Health Sciences, University of Antwerp and Division of Neurology, Antwerp University Hospital, Edegem, Belgium;4. Department of Scientific Coordination and Biostatistics, Antwerp University Hospital, Edegem, Belgium |
| |
| Abstract: | Background aimsDendritic cell (DC)-based immunotherapy has shown potential to counteract autoimmunity in multiple sclerosis (MS).MethodsWe compared the phenotype and T-cell stimulatory capacity of in vitro generated monocyte-derived DC from MS patients with those from healthy controls.ResultsExcept for an increase in the number of C-C chemokine receptor 7–expressing DC from MS patients, no major differences were found between groups in the expression of maturation-associated membrane markers or in the in vitro capacity to stimulate autologous T cells.ConclusionsOur observations may pave the way for the development of patient-tailored DC-based vaccination strategies to treat MS. |
| |
| Keywords: | dendritic cells immunotherapy multiple sclerosis T cell activation |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
